DE60030283D1 - Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen - Google Patents

Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Info

Publication number
DE60030283D1
DE60030283D1 DE60030283T DE60030283T DE60030283D1 DE 60030283 D1 DE60030283 D1 DE 60030283D1 DE 60030283 T DE60030283 T DE 60030283T DE 60030283 T DE60030283 T DE 60030283T DE 60030283 D1 DE60030283 D1 DE 60030283D1
Authority
DE
Germany
Prior art keywords
increasing
bioverability
compositions
pharmaceutical compounds
prepared pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030283T
Other languages
English (en)
Other versions
DE60030283T2 (de
Inventor
Henricus Schellens
Hermanus Schinkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Ventures Ltd
Original Assignee
Cancer Research Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Ventures Ltd filed Critical Cancer Research Ventures Ltd
Application granted granted Critical
Publication of DE60030283D1 publication Critical patent/DE60030283D1/de
Publication of DE60030283T2 publication Critical patent/DE60030283T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60030283T 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen Expired - Lifetime DE60030283T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012066 1999-05-17
NL1012481 1999-06-30
NL1012481 1999-06-30
PCT/NL2000/000331 WO2000069390A2 (en) 1999-05-17 2000-05-17 Compositions for improving bioavailability of orally administered drugs

Publications (2)

Publication Number Publication Date
DE60030283D1 true DE60030283D1 (de) 2006-10-05
DE60030283T2 DE60030283T2 (de) 2007-09-20

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60045114T Expired - Lifetime DE60045114D1 (de) 1999-05-17 2000-05-17 Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
DE60030283T Expired - Lifetime DE60030283T2 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60045114T Expired - Lifetime DE60045114D1 (de) 1999-05-17 2000-05-17 Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1189637B1 (de)
AT (2) ATE337016T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60045114D1 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2000069390A2 (en) * 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
WO2006012958A2 (en) * 2004-07-01 2006-02-09 The Netherlands Cancer Institute Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
WO2006021932A1 (en) 2004-08-27 2006-03-02 Koninklijke Philips Electronics, N.V. Electronically and remotely controlled pill and system for delivering at least one medicament
ATE485074T1 (de) * 2004-11-29 2010-11-15 Koninkl Philips Electronics Nv Elektronisch gesteuerte tablette
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
WO2009104110A1 (en) * 2008-02-18 2009-08-27 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
JP5681861B2 (ja) * 2008-03-31 2015-03-11 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ センサを有する嚥下型カプセルを作成する方法
JP5627569B2 (ja) 2008-04-30 2014-11-19 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 新規基質に基づくｐｅｔ造影剤
WO2009153739A1 (en) * 2008-06-19 2009-12-23 Koninklijke Philips Electronics N.V. Device for delivery of powder like medication in a humid environment
US8961498B2 (en) * 2008-06-25 2015-02-24 Medimetrics Personalized Drug Delivery Electronic pill comprising a plurality of medicine reservoirs
EP2464414B1 (de) 2009-08-12 2013-06-12 Medimetrics Personalized Drug Delivery B.V. Wirkstofffreisetzungsvorrichtung mit komprimierbarem wirkstoffreservoir
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
CZ283038B6 (cs) 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
ATE152443T1 (de) * 1992-07-10 1997-05-15 Glaxo Lab Sa Anilide-derivate
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1996011007A1 (en) 1994-10-05 1996-04-18 Glaxo Wellcome Inc. Parenteral pharmaceutical compositions containing gf120918a
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
UA74767C2 (en) 1997-05-27 2006-02-15 Baker Norton Pharma Method and composition for oral use of taxanes in patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2319715C (en) * 1998-02-05 2012-08-07 University Of Maryland, Baltimore Breast cancer resistance protein (bcrp) and the dna which encodes it
AU764370B2 (en) 1998-06-18 2003-08-14 George Washington University, The Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6476043B1 (en) 1998-08-05 2002-11-05 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2000069390A2 (en) * 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
AU4955200A (en) 2000-12-05
ES2270834T3 (es) 2007-04-16
EP1749540B1 (de) 2010-10-13
WO2000069390A2 (en) 2000-11-23
ATE337016T1 (de) 2006-09-15
DE60030283T2 (de) 2007-09-20
EP1189637A2 (de) 2002-03-27
ATE484295T1 (de) 2010-10-15
EP1749540A3 (de) 2007-05-30
US7030132B2 (en) 2006-04-18
DK1189637T3 (da) 2006-12-11
WO2000069390A3 (en) 2001-12-13
DE60045114D1 (de) 2010-11-25
PT1189637E (pt) 2007-01-31
EP1189637B1 (de) 2006-08-23
CY1105795T1 (el) 2011-02-02
US20020128282A1 (en) 2002-09-12
EP1749540A2 (de) 2007-02-07
US20060128743A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ID29181A (id) Kombinasi formoterol dan garam tiotropium
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
DE69636531D1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
DE69526428D1 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
DE60325354D1 (de) Topisch anwendbare pharmazeutische zubereitung
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ID30171A (id) Kombinasi formoterol dan mometason furoat untuk asma
ATE292453T1 (de) Antivirale arznei
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
SE8100276L (sv) Farmaceutiskt aktiv komposition omfattande ketoner och heterocykliska foreningar
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
EA200701409A1 (ru) Новая композиция
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
BG108144A (en) New use
ITMI992736A0 (it) Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi
ECSP993090A (es) Composicion farmaceutica de proteinas erizo y su uso

Legal Events

Date Code Title Description
8364 No opposition during term of opposition